PipelineReview.com. Biopharmaceutical News & Clinical Trials
网页PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab …
网页4 小时之前 · With three new indications, BIMZELX ® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for the treatment of four chronic immune-mediated inflammatory diseases ; Approval in active PsA is supported by two Phase 3 studies in which bimekizumab-bkzx showed statistically significant improvements vs. placebo at Week 16 in both joint and skin symptoms, across ...
All news - Pipelinereview
网页2024年9月16日 · PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
RYBREVANT® (amivantamab-vmjw) plus standard of care …
网页3 天之前 · Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT ® this year, with four indications overall. RARITAN, NJ, USA I September 19, 2024 I Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT ® (amivantamab-vmjw) in combination with standard of care ...
Transcenta Updates Encouraging Efficacy Data from First-line …
网页4 天之前 · PRINCETON, NJ, USA and SUZHOU, China I September 18, 2024 I Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today ...
Vaccines - Pipelinereview
网页2024年9月12日 · HDT bio’s Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year SEATTLE, WA, USA I September 17, 2024 I HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies, is proud to announce its pivotal role in PROVIDENT (Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics Against […]
Samsung Bioepis and Biogen Receive Positive CHMP Opinion for ...
网页2 天之前 · OPUVIZ™, a biosimilar referencing Eylea 1 (aflibercept), is Samsung Bioepis and Biogen’s second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency; INCHEON, South Korea and CAMBRIDGE, MA, USA I September 20, 2024 I Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency’s (EMA ...
TREMFYA® (guselkumab) demonstrates superiority versus …
网页2024年5月21日 · Data from GALAXI 2 & 3 showed TREMFYA ® was superior to STELARA ® in all pooled endoscopic endpoints. WASHINGTON, DC, USA I May 21, 2024 I Johnson & Johnson today announced the first Phase 3 results for TREMFYA ® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), which demonstrated superiority of both subcutaneous (SC) maintenance doses (200 mg every 4 ...
Press Release: New 48-week frexalimab phase 2 data
网页2024年4月17日 · New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis. Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis
GSK Announces Positive Topline Data on Co-Administration of …
网页4 天之前 · These data advance the science of co-administration of recommended adult vaccines. PHILADELPHIA, PA, USA I September 18, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine ...